Lymphoma. Hodgkinlymfomen and non-Hodgkin's disease
Information on current developments in both regular and alternative or complementary treatments and resources for lymphoma - non-Hodgkin's lymphoma and Hodgkin's disease at all stages.
Recent articles in left column more or less in alphabetical order classified
Experiences of cancer patients with complementary approaches can be found by experience stories on our website and there are also some videos of experiences of cancer patients with complementary approaches to see. To click on video button top left of this page. Or visit the website of the SNFK information where movies are shown on complementary approaches to cancer.
Chemo and effect in lymphoma: Rituximab - Mabthera added to CHOP therapy for lymphoma - B-cell lymphoma shows superior results in randomized phase III study. Update November 27, 2010
March 25, 2005: Source: Clinical Options
Superior Outcome When Rituximab Added to CHOP-14 in Elderly Patients With Diffuse Large B Cell Lymphoma
RICOVER-60, a multicenter, phase III, randomized trial
Summary of Key Conclusions
Adding rituximab to cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) -14 Produced superior outcomes in elderly Patients with diffuse large B-cell lymphoma (DLBCL)
8 cycles of CHOP-14 showed better survival Than trend or 6 cycles of CHOP-14, but beneficial effects masked by Addition of rituximab
Current results with 6 or 8 cycles of CHOP-14 plus rituximab (R-CHOP-14) represents best results to date in elderly DLBCL patiënten
Main Findings
Intent-to-treat analysis
Rituximab significantly Addition Affected FFTF (FFTF = disease-free time) 6 cycles of CHOP-14 (n = 414) vs 8 cycles of CHOP-14 (n = 413): 62% vs. 64%, respectively (P = .23) CHOP 14 (n = 413) vs R-CHOP-14 (n = 414): 57% vs. 70%, respectively (P = .000025)
Trend of Increased survival in R-CHOP-14 vs. CHOP-14 but not significantly (P = .13)
Median observation time: 26 months
Favorable Increase in survival among elderly DLBCL patiënten compared with historic controls receiving CHOP-21
74% projected survival in RICOVER-60 trial with R-CHOP-14 treatment
Groupe d'Etude des Lymphomes 98.5 de l'Adulte trial demonstrated 64% and 55% survival in elderly DLBCL Patients Treated with 8 cycles of CHOP-21 with and without rituximab, respectively Other Outcomes
Strong adherence to protocol (> 96% in all groups)
Increased neurotoxicity in Patients Treated with Rituximab
Reference
Pfreundschuh M, Kloet M, Schmits R, et al Six, not eight cycles of bi-weekly CHOP with rituximab (R-CHOP-14) is the preferred treatment for elderly Patients with diffuse large B-cell lymphoma (DLBCL): results RICOVER-60 of the trial of the Germantown High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Program and abstracts of the 47th Annual Meeting of the American Society of Hematology, 10 to 13 December 2005, Atlanta, Georgia. Abstract 13.
